Viking Therapeutics, Inc. (VKTX)

Investment strategist Shay Boloor has outlined ten sub-$10 billion market-cap companies he believes are positioned to benefit from powerful long-term trends heading into 2026.

Together, these stocks offer you a balanced mix of growth and safety. These companies span a number of industries, and many are leaders in their markets.

Frontier Capital Management Co. LLC raised its stake in shares of Viking Therapeutics, Inc. (NASDAQ: VKTX) by 52.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 638,204 shares of the biotechnology company's stock after purchasing an additional 220,396

The best-performing stock on this list is up just 4% this year. Investors may be undervaluing these companies' growth opportunities.

Viking Therapeutics is positioned for a pivotal 2026, advancing both injectable and oral VK2735 in obesity, with pipeline depth from an emerging amylin agonist program. VKTX's oral VK2735 has demonstrated unmatched double-digit weight loss in 13 weeks, potentially establishing leadership in the oral obesity drug segment. Despite a robust $714M cash position and a 4/5 conviction rating, risks include Phase III trial costs, competitive pressures, and potential dilution.

Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Viking Therapeutics could enter the weight loss market by 2029. The company's leading candidate looks very promising.

SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Piper Sandler 37th Annual Healthcare Conference. The conference will take place December 2-4, 2025, in New York, New York.

If you want to invest in top healthcare stocks, both of these are worth consideration. Pfizer is moving past the pandemic era, and tremendous growth could be ahead.

The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it's set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.

Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?

Mid-cap stocks can come with risks, but also a ton of upside in the long run. The stocks listed here offer exciting growth opportunities across multiple industries.

Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.

Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also could deliver a win for investors.

Viking Therapeutics, Inc. ( VKTX ) Jefferies London Healthcare Conference 2025 November 19, 2025 3:00 AM EST Company Participants Brian Lian - President, CEO & Director Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division All right. Welcome, everyone, to Jefferies Healthcare London Conference.